Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
14 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Xeloda“
Suchtreffer
Begriffe & Kennungen
Xeloda · 4.8 · Elderly patients (see section 4.2): An analysis of safety data in patients ≥60 years of age treated with capec
Eintrag öffnenXeloda · 4.8 · Encephalopathy: In addition to the ADRs described in tables 4 and 5, and based on the above pooled analysis fr
Eintrag öffnenXeloda · 4.8 · Exposure to crushed or cut capecitabine tablets: In the instance of exposure to crushed or cut capecitabine ta
Eintrag öffnenXeloda · 4.8 · Gender The results of a meta-analysis of 14 clinical trials with data from over 4700 patients treated with cap
Eintrag öffnenXeloda · 4.8 · Hand-foot syndrome (see section 4.4): For the capecitabine dose of 1250 mg/m2 twice daily on days 1 to 14 ever
Eintrag öffnenXeloda · 4.8 · Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medi
Eintrag öffnenXeloda · 4.8 · Some of the ADRs are reactions commonly seen with the combination medicinal product (e.g. peripheral sensory n
Eintrag öffnenXeloda · 4.8 · Special populations
Eintrag öffnenXeloda · 4.8 · Summary of the safety profile
Eintrag öffnenXeloda · 4.8 · Tabulated list of adverse reactions
Eintrag öffnenXeloda · 4.8 · The most commonly reported and/or clinically relevant treatment-related adverse drug reactions (ADRs) were gas
Eintrag öffnenXeloda · 4.8 · The overall safety profile of capecitabine is based on data from over 3000 patients treated with capecitabine
Eintrag öffnenXeloda · 4.8 · The results of a meta-analysis of 14 clinical trials with data from over 4700 patients treated with capecitabi
Eintrag öffnenXeloda · 4.8 · The results of a meta-analysis of 14 clinical trials with data from over 4700 patients treated with capecitabi
Eintrag öffnen